On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.

On the news front, the life sciences tools and services sector experienced a broad-based rally, with peer WUXI APPTEC surging 11.91%, PHARMARON up 5.73%, GENSCRIPT BIO up 4.79%, and WUXI XDC up 3.74%, indicating strong sector-wide momentum in the CXO space.

Multiple positive catalysts have converged for the sector. The company's board is scheduled to review interim results on August 25, creating earnings anticipation. Additionally, the company has maintained an active share buyback program, repurchasing over HKD 1.17 billion worth of shares through late June. Its MFG8 drug substance facility recently received FDA Pre-License Inspection approval for a potential blockbuster autoimmune therapy, marking a key milestone for commercial-scale manufacturing capability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)